Zhiyi is a leading company in live biotherapeutics (LBPs) and next-generation probiotics in China. The company’s SK08（Bacteroides fragilis） was approved for clinical trials in November 2019.It is the first LBP in China with immense influence. Zhiyi has established a complete technical system for the spectra of microorganisms and pathogenic bacteria, the isolation and target identification of new functional strains as well as the development of new live biotherapeutics and active ingredients. Zhiyi also has a complete industrialization platform from preclinical to NDA.
Company Details
- Employees
- 5
- Address
- 广州市, Cn
- Industry
- Biotechnology
- Website
- https://www.zypharm.com.cn/
- Keywords
- 生物技术 and 制药.
- HQ
- 广州市
Zhiyi Biotechnology Questions
Zhiyi Biotechnology's website is https://www.zypharm.com.cn/
Zhiyi Biotechnology's LinkedIn profile is https://cn.linkedin.com/company/zhiyibiotechnology
Zhiyi Biotechnology has
5 employees.
View email and phone details for 5
employees at Zhiyi Biotechnology.
Zhiyi Biotechnology's industry is
Biotechnology
Zhiyi Biotechnology's top competitors are
Boehringer Ingelheim,
Astellas Pharma,
Avant,
Bennu Biotherapeutics,
上海复星医药(集团)股份有限公司,
Affamed Therapeutics,
Sichuan Greentech Bioscience Co., Ltd.,
Nuance Pharma,
Max Planck Institute For Psycholinguistics,
Zydus Group.
Zhiyi Biotechnology's categories are Biotechnology
